985 related articles for article (PubMed ID: 15554747)
1. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents.
Toren P; Ratner S; Laor N; Weizman A
Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747
[TBL] [Abstract][Full Text] [Related]
2. [Metabolic side effects of risperidone in early onset schizophrenia].
Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R
Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267
[TBL] [Abstract][Full Text] [Related]
3. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
Krzystanek M; Krupka-Matuszczyk I
Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
[TBL] [Abstract][Full Text] [Related]
4. Tolerability profile of atypical antipsychotics in children and adolescents.
Stigler KA; Potenza MN; McDougle CJ
Paediatr Drugs; 2001; 3(12):927-42. PubMed ID: 11772153
[TBL] [Abstract][Full Text] [Related]
5. Using antipsychotic agents in older patients.
Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
[TBL] [Abstract][Full Text] [Related]
6. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management.
Haddad PM; Wieck A
Drugs; 2004; 64(20):2291-314. PubMed ID: 15456328
[TBL] [Abstract][Full Text] [Related]
7. Off-label second generation antipsychotics for impulse regulation disorders: a review.
Scheltema Beduin A; de Haan L
Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
[TBL] [Abstract][Full Text] [Related]
8. [Atypical antipsychotics and sexual dysfunction: five case-reports associated with risperidone].
Haefliger T; Bonsack C
Encephale; 2006; 32(1 Pt 1):97-105. PubMed ID: 16633296
[TBL] [Abstract][Full Text] [Related]
9. Acute Antipsychotic Treatment of Children and Adolescents With Schizophrenia-Spectrum Disorders: A Systematic Review and Network Meta-Analysis.
Pagsberg AK; Tarp S; Glintborg D; Stenstrøm AD; Fink-Jensen A; Correll CU; Christensen R
J Am Acad Child Adolesc Psychiatry; 2017 Mar; 56(3):191-202. PubMed ID: 28219485
[TBL] [Abstract][Full Text] [Related]
10. [Prescription of olanzapine in children and adolescent psychiatric patients].
Frémaux T; Reymann JM; Chevreuil C; Bentué-Ferrer D
Encephale; 2007; 33(2):188-96. PubMed ID: 17675914
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
12. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review.
Newcomer JW
CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156
[TBL] [Abstract][Full Text] [Related]
13. Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials.
Jensen PS; Buitelaar J; Pandina GJ; Binder C; Haas M
Eur Child Adolesc Psychiatry; 2007 Mar; 16(2):104-20. PubMed ID: 17075688
[TBL] [Abstract][Full Text] [Related]
14. Tolerability of atypical antipsychotics.
Stanniland C; Taylor D
Drug Saf; 2000 Mar; 22(3):195-214. PubMed ID: 10738844
[TBL] [Abstract][Full Text] [Related]
15. Treatment challenges and safety considerations for antipsychotic use in children and adolescents with psychoses.
McConville BJ; Sorter MT
J Clin Psychiatry; 2004; 65 Suppl 6():20-9. PubMed ID: 15104523
[TBL] [Abstract][Full Text] [Related]
16. The use of atypical antipsychotics in the management of schizophrenia.
Campbell M; Young PI; Bateman DN; Smith JM; Thomas SH
Br J Clin Pharmacol; 1999 Jan; 47(1):13-22. PubMed ID: 10073734
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of atypical antipsychotics in children and adolescents.
Caccia S
Paediatr Drugs; 2013 Jun; 15(3):217-33. PubMed ID: 23588704
[TBL] [Abstract][Full Text] [Related]
18. Atypical antipsychotic agents: a critical review.
Worrel JA; Marken PA; Beckman SE; Ruehter VL
Am J Health Syst Pharm; 2000 Feb; 57(3):238-55. PubMed ID: 10674777
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
